Furosemide is a small molecule NKCC2 inhibitor drug, blocking the sodium-potassium-chloride co-transporter in the kidney's ascending loop of Henle.

Johnson & Johnson has filed an additional request with the FDA for authorization of its DARZALEX FASPRO formula as a therapy option for newly identified multiple myeloma cases eligible for transplant.

KLONOPIN (clonazepam) is a benzodiazepine medication that was first approved by the FDA in 1975 for the treatment of seizure disorders and panic disorder.

U.S. and Japanese authorities have approved filings for Bristol Myers Squibb's Breyanzi, aimed at treating recurrent Follicular and Mantle Cell Lymphomas.

Viagra relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.

Vertex Reveals Encouraging Outcomes from Phase 3 Trials of VX-548 for Moderate to Intense Short-Term Pain Management.

Citalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines.

CellVax Therapeutics has received approval from the FDA for its IND submission for FK-PC101, a new individualized immunotherapy treatment for cancer.

Clonidine lowers blood pressure by stimulating α2 receptors in the brain, which results in relaxation of many arteries.

DP Tech has revealed its selection of a developmental contender, a promising top-tier Kv1.3 blocker aimed at tackling immune disorders like IBD and AD.

SINGULAIR® (Montelukast sodium) is a drug for treating asthma, exercise-induced bronchoconstriction (EIB), and allergic rhinitis.

EicOsis Human Health has announced the advancement of its clinical research program, beginning a Phase 1b trial to assess the safety of its experimental drug, EC5026, through increasing dosages.